Compugen (NASDAQ:CGEN) Posts Quarterly Earnings Results, Misses Expectations By $0.20 EPS

Compugen (NASDAQ:CGEN) issued its quarterly earnings results on Tuesday. The biotechnology company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.21 by ($0.20), Zacks reports. The company had revenue of $17.13 million for the quarter, compared to the consensus estimate of $17.67 million. Compugen had a net margin of 2.67% and a return on equity of 2.61%. During the same quarter in the previous year, the business earned ($0.11) earnings per share.

Compugen Trading Up 2.2 %

NASDAQ:CGEN opened at $1.62 on Thursday. The company has a market cap of $145.01 million, a PE ratio of 79.50 and a beta of 2.64. The company has a 50 day simple moving average of $1.77 and a two-hundred day simple moving average of $1.88. Compugen has a 12 month low of $0.58 and a 12 month high of $3.03.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised Compugen from a “hold” rating to a “buy” rating in a research report on Thursday, August 15th.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.